APAnna Petrackova

Anna Petrackova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Petrackova has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Eva Kriegova

    Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic

    4 shared publications
  • Andrea Smrzova

    Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Olomouc, Czech Republic

    2 shared publications
  • Frantisek Mrazek

    Department of Immunology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

    2 shared publications
  • Jakub Savara

    Department of Immunology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic; Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic

    2 shared publications
  • Jirina Manakova

    Palacký University Olomouc and University Hospital Olomouc Department of Immunology, Faculty of Medicine and Dentistry Hnevotinska 3, 77900 Olomouc

    2 shared publications
  • Martina Skacelova

    Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Olomouc, Czech Republic

    2 shared publications

Latest Publications

  • Open Access

    Multiplatform comparisons and annotation of structural variants highlight the utility of the T2T reference genome in human diagnostics

    by Jakub Savara, Tomas Novosad, Petr Gajdos, Anna Petrackova, Marek Behalek, Jirina Manakova, Filip Ctvrtlik, Jiri Minarik, Tomas Papajik, Eva Kriegova

    Background: Structural variants (SVs) are increasingly recognized as key contributors to human diseases. However, our understanding of SVs in health and disease is limited, mainly due to their structural complexity and variable length in individuals, as well as limitations inherent to the available genomic technologies and reference genome used. Results: To systematically evaluate SVs across human whole-genome samples using hg38/GRCh38 and gapless T2T-CHM13 references, we introduced an innovative multiplatform approach, LongReadChecker (LoReC), which advances SV comparison and annotation based on distance variance, intersection, gene overlap, and the closest SV in the clinical database. Comparison of the performance in detecting SVs from public and our own whole-genome datasets from short-read sequencing (SRS), available long-read sequencing (LRS) platforms, and optical genome mapping (OGM) revealed that most SVs detected by SRS were confirmed by LRS, but LRS can identify twice as many SVs (25,000 SVs/genome) with greater read mapping accuracy. Our LongReadChecker (LoReC) analysis further highlights the utility of the T2T-CHM13 reference in SV detection, as 20% more deletions and 20% less insertions were detected compared with hg38/GRCh38, which was particularly evident in long-read datasets. Since 80% of the SVs detected by LRS/SRS are smaller than 0.5 kbp, OGM did not detect them. Conclusions: Our study revealed that introducing distance variance, intersection, gene overlap, and the closest SV in the clinical database may help compare and annotate SVs in diagnostics. Our data showed that LRS, together with T2T-CHM13 gapless sequences, can improve the diagnostics of patients with human diseases when SRS fails to identify the cause.


  • Open Access

    Blood gene expression of Toll-like receptors in SLE patients with lupus nephritis or neuropsychiatric systemic lupus erythematosus

    by Marketa Dudkova, Anna Petrackova, Martin Radvansky, Martina Skacelova, Jakub Videman, Jirina Manakova, Veronika Smotkova Kraiczova, Milos Kudelka, Andrea Smrzova, Katerina Langova, et al.

    To determine differences in the blood innate gene expression signatures of systemic lupus erythematosus (SLE) patients across various organ manifestations and disease activity, with a focus on lupus nephritis (LN) and central nervous system (CNS) involvement. Toll-like receptor family (TLR 1–10) mRNA expression was investigated in peripheral blood mononuclear cells from patients with SLE (n = 74) and healthy controls (n = 34). We compared patients with histologically confirmed active LN or neuropsychiatric systemic lupus erythematosus (NPSLE) with patients without these symptoms. The expression of TLR mRNA was determined by RT‒qPCR using a high-throughput SmartChip Real-Time-qPCR system (WaferGen). Multivariate analysis and nonparametric statistics were used for data analysis to assess the associations between TLRs and disease activity and severity. TLR4 (0.044 vs. 0.081, p = 0.012) was upregulated and TLR10 (0.009 vs. 0.006, p = 0.0007) was downregulated in the whole cohort of SLE patients compared to healthy controls. A comparison of the active LN group with participants without kidney involvement revealed increased expression of TLR2 (0.078 vs. 0.03, p = 0.009), and TLR5 (0.035 vs. 0.017, p = 0.03). Moreover, a significant difference was observed in TLR9 expression between inactive LN and the control group (0.014 vs. 0.009, p = 0.01), together with borderline correlation in TLR2 expression (0.04 vs. 0.03, p = 0.06). Receiver operating characteristic (ROC) curve analysis revealed that TLR1 and TLR2 expression were the best potential diagnostic markers for active LN. The NPSLE group showed upregulation of TLR1 (0.088 vs. 0.048, p = 0.01), TLR4 (0.173 vs. 0.066, p = 0.0003) and TLR6 (0.087 vs. 0.036, 0.007). Our correlation analysis supported the close relationships among the expression of individual TLRs in the whole lupus cohort and its subgroups. Our study revealed differences in TLR expression between a lupus cohort and healthy controls. Additionally, our analysis provides insight into specific TLR expression in cases with severe organ manifestations, such as LN and NPSLE. The multiple mutual relationships of TLRs demonstrate the activation of innate immunity in SLE and suggest promising targets for future therapies or diagnostics.


  • Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers

    by Anna Petrackova, Jakub Savara, Peter Turcsanyi, Petr Gajdos, Tomas Papajik, Eva Kriegova

    Summary: Germline pathogenic ATM (ataxia‐telangiectasia mutated) variants are associated with the risk of multiple cancers; however, genetic testing reveals a large number of ATM variants of uncertain significance (VUS). Here, we studied germline ATM variants occurring in a real‐world cohort of 336 patients with chronic lymphocytic leukaemia (CLL) and public cancer whole‐exome/genome‐sequencing datasets (445 CLL, 75 mantle cell lymphoma, 216 metastatic breast cancer, 140 lung cancer patients). We found that two‐thirds of rare germline ATM variants are pathogenic (18%–50%) or VUS‐predicted pathogenic (50%–82%), depending on cancer type and reaching a prevalence of up to 8%, and one‐third are VUS‐predicted benign. Patients with both pathogenic and VUS‐predicted pathogenic variants, all heterozygous, mostly missense, are more predisposed to biallelic ATM inactivation by acquiring deletion (del)11q than patients without these variants, similar to patients with somatic ATM variants. A functional assay of ATM activity in primary CLL cells proved that VUS‐predicted pathogenic ATM variants partially reduce ATM activity and concurrent del(11q) leads to complete loss of ATM activity. The rare germline variants were associated with reduced progression‐free survival in CLL on novel agents, comparable to somatic ATM or TP53 disruptions. Our results highlight the need to determine the pathogenicity of VUS in clinically relevant genes such as ATM.


  • Modulatory Effect of the Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen on Circulating Immune Cells in Systemic Lupus Erythematosus

    by Gabriela Gabcova, Pavel Horak, Zuzana Mikulkova, Martina Skacelova, Sarka Zehnalova, Andrea Smrzova, Anna Petrackova, Frantisek Mrazek, Eva Kriegova

    A Euro-Lupus regimen of low-dose intravenous cyclophosphamide (CFA) is commonly used to treat severe organ manifestations of systemic lupus erythematosus (SLE), particularly lupus nephritis (LN). There are no data on the distributions and dynamics of immune cell populations in patients with various treatment outcomes. The circulating immune cells of 11 female SLE patients were assessed before and after Euro-Lupus regimen (cumulative dose of 3000 mg CFA) by flow cytometry together with those of 16 healthy women. A subanalysis was performed in LN patients who achieved complete remission (CR; n = 3), partial remission (PR; n = 4), and no response (NR; n = 2). In SLE, the Euro-Lupus regimen decreased the percentage and absolute count of B cells; increased the percentage of CD8+ T cells, T regulatory cells, neutrophils, and monocyte subsets; and activated T and NK cells compared to healthy controls (P < 0.050). Patients with LN achieving CR had significantly lower proportions of CD27+ B memory cells compared to poor responders (PR/NR, P = 0.035). The post-treatment percentages and absolute numbers of B cells, T cells, NK cells, monocytes, and neutrophils showed high inter-individual variability with no association with treatment outcome. Our pilot study revealed the dynamics of changes in immune cell populations in SLE patients during a Euro-Lupus regimen, mainly the lowering of B cells. In LN patients who achieved CR, a lower proportion of CD27+ B memory cells was evident compared to poor responders (PR/NR). Further studies on usefulness of monitoring immune cells for treatment response prediction on larger cohorts are needed.